• Health Canada cleared AbbVie’s EPKINLY (epcoritamab) with lenalidomide, rituximab for relapsed or refractory follicular lymphoma in adults.
• Use targets grade 1-3A disease in patients with at least one prior systemic therapy.
• Phase III EPCORE FL-1 showed a 79% lower risk of progression or death versus lenalidomide-rituximab alone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609240701CANADANWCANADAPF_C8852) on September 24, 2026, and is solely responsible for the information contained therein.